Open-Label Study Comparing Efficacy and Safety of ATV/RTV+3TC With ATV/RTV+TDF/FTC in HIV-Infected, Treatment Naïve Subjects, Followed by Treatment With ATV/RTV+3TC

A 48-Week, Randomized, Open-Label Phase 3B Study Comparing the Antiviral Efficacy and Safety of ATV/RTV 3TC With ATV/RTV Plus TDF/FTC In HIV-1-Infected, Treatment-Naïve Subjects, Followed By a 48-Week Period on ATV/RTV Plus 3TC

The primary objective of this study in antiretroviral (ARV)-naïve Human immunodeficiency virus 1 (HIV-1) ribonucleic acid infected subjects is to compare the response rate at Week 48 of a daily regimen of Atazanavir (ATV)/ Ritonavir (RTV)HS 300/100 mg combined with either one additional drug [Lamivudine (3TC) 300 mg daily] or 2 additional drugs [Tenofovir/Emtricitabine(TDF/FTC) 300/200 mg daily].

Study Overview

• Status: Terminated
• Conditions: HIV
• Intervention / Treatment: Drug: Atazanavir; Drug: Ritonavir; Drug: Lamivudine; Drug: Tenofovir/Emtricitabine

• Study Type: Interventional
• Enrollment (Actual): 3
• Phase: Phase 3

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria

- Signed Written Informed Consent.

i) Freely given informed consent must be obtained from subjects prior to clinical trial participation, including informed consent for any screening procedures conducted to establish subject eligibility for the trial.

ii) A freely given Pharmacokinetics (PK) sub-study consent form must be obtained from the subset of subjects participating in the intensive PK sub-study.

- Target Population.

i) Treatment-naive HIV-1-infected subjects (< 48 hours of any ARV is allowed).

ii) Subjects who have an HIV-1 Ribonucleic acid (RNA) level ≥ 1000 c/mL at screening.

iii) Subjects who have a Antigenic marker of helper/inducer T lymphocytes (CD4) + cell count > 100 cells/mm3.

- Age and Reproductive Status.

i) Men and women, 18 years of age or older (or minimum age as determined by local regulatory or legal requirements).

ii) Women of childbearing potential (WOCBP) must use highly effective methods of birth control for up to 8 weeks after the last dose of investigational product to minimize the risk of pregnancy. WOCBP must follow instructions for birth control for the entire duration of the study including a minimum of 30 days after dosing has been completed.

iii) Acceptable methods of highly effective birth control include:.

A. Condom with spermicide.

B. Diaphragm and spermicide.

C. Cervical cap and spermicide

- Since acceptable and available methods of contraception vary among different countries, participating women may choose their preferred contraceptive method atazanavir AI424494 BMS-232632 Clinical Protocol Date: 31-01-2012 33 based on physician recommendations. Caution is warranted with co-administration of oral contraceptives (ethinyl estradiol and norethindrone).

i) Women must have a negative serum or urine pregnancy test [minimum sensitivity 25 IU/L or equivalent units of Human chorionic gonadotropin (HCG)] within 24 hours prior to the start of investigational product.

ii) Women must not be breastfeeding.

iii) Sexually active fertile men must use highly effective birth control if their partners are WOCBP.

Exclusion Criteria

- Target Disease Exceptions.

i) Subjects who have an HIV-1 RNA level ≥500,000 c/mL at screening.

ii) Screening HIV genotype showing resistance to any component of the study regimen (ATV, RTV, 3TC, TDF/FTC).

iii) Previously documented HIV-2 infection.

- Medical History and Concurrent Diseases.

i) Acute or chronic hepatitis B virus (HBV) or Acute hepatitis C virus (HCV) co-infection.

- Note Chronic co-infection with hepatitis C is not exclusion criteria. Subjects with acute hepatitis C may have the option to be screened after the event has evolved into a chronic infection.

i) Presence of a newly diagnosed HIV-related opportunistic infection (OI) or any medical condition requiring acute therapy at the time of enrollment. Subjects on stable maintenance therapy for an OI may be enrolled.

ii) Primary HIV infection.

iii) History or current cardiac disease, defined by presence of arrhythmias, ischemic disease, or a conduction abnormality including left bundle branch block (LBB) or left anterior fascicular block (LAFB), 2nd or 3rd-degree atrioventricular block (AVB), or any cardiac abnormality deemed clinically significant by the investigator. In addition, the following Electrocardiogram (ECG) findings are exclusionary:.

A. PR Interval > 260 msec (severe 1st degree AV Block).

B. QRS Interval > 120 msec.

iv) Moderate-to-severe hepatic insufficiency.

v) Obstructive liver disease.

vi) Recent therapy with agents having significant systemic myelosuppressive, neurotoxic, pancreatotoxic, hepatotoxic or cytotoxic potential within 3 months of study start or the expected need for such therapy at the time of enrollment, or therapy with methadone or ribavirin/interferons or treatment with neurotoxic drugs or drugs that affect CYP3A4.

vii) Concomitant administration of a proton pump inhibitor (PPI) or H2 blocker or any other drug with potential interaction with the investigational products.

viii) Life expectancy < 1 year according to the judgment of the investigator.

ix) Active alcohol or substance use sufficient, in the investigator's opinion, to prevent adequate compliance with study therapy or to increase the risk of developing pancreatitis or chemical hepatitis.

x) History or ongoing psychiatry disorder.

xi) Any other clinical conditions or prior therapy that, in the opinion of the investigator, would make the subject unsuitable for study or unable to comply with the dosing requirements.

- Physical and Laboratory Test Findings.

i) Screening laboratory analysis shows any of the following abnormal laboratory results:.

A. Grade IV glucose.

B. Grade IV electrolytes.

C. Grade IV transaminases.

D. Grade IV hematology.

ii) Calculated creatinine clearance < 60 mL/min as estimated by the Cockcroft-Gault equation.

• Allergies and Adverse Drug Reaction.

  i) Hypersensitivity to any component of the study drug formulations.

• Sex and Reproductive Status.

  i) Pregnancy.

• Other protocol-defined Inclusion/Exclusion criteria apply.

  i) Prisoners or subjects who are involuntarily incarcerated.

ii) Subjects who are compulsorily detained for treatment of either a psychiatric or physical (eg, infectious disease) illness.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Arm1: ATV/RTVHS+3TC	Drug: Atazanavir; Capsule, oral, 300 mg, Once daily (QD), 96 weeks; Drug: Ritonavir; Tablets, oral, 100 mg, QD, 96 Weeks; Other Names: Ritonavir high sensitivity (RTV HS); Drug: Lamivudine; Tablet, oral, 300 mg, QD, 96 Weeks
Active Comparator: Arm2: ATV/RTVHS+TDF/FTC	Drug: Atazanavir; Capsule, oral, 300 mg, Once daily (QD), 96 weeks; Drug: Ritonavir; Tablets, oral, 100 mg, QD, 96 Weeks; Other Names: Ritonavir high sensitivity (RTV HS); Drug: Tenofovir/Emtricitabine; Tablets, oral, 300/200 mg, QD, 48 Weeks

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Proportion of Participants With HIV-1 RNA < 40 c/mL at Week 48	Proportion of subjects with HIV-1 RNA < 40 c/mL at Week 48.	Week 48

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Proportion of Participants With HIV-1 RNA < 400 c/mL at Week 48	Proportion of Participants with HIV-1 RNA < 400 c/mL at Week 48.	Week 48
Proportion of Participants With HIV-1 RNA < 40 c/mL and < 400 c/mL at Week 96	proportion of subjects with HIV-1 RNA < 40 c/mL and < 400 c/mL at Week 96.	Week 96
Incidence of Adverse Events Through Weeks 48 and 96	Incidence of Adverse Events through weeks 48 and 96 including serious adverse events (SAEs) and adverse events (AEs) leading to discontinuation. There were no SAEs or AEs reported in this early terminated study.	through weeks 48 and 96
Percent Change From Baseline in eGFR and Bone Mineral Density at Weeks 48 and 96	Percent change from baseline in eGFR and bone mineral density at weeks 48 and 96.	Weeks 48 and 96
Incidence of Newly Emergent Genotypic Substitutions and Phenotypic Resistance to Study Drugs for Virologic Failures Through Week 48 and 96	Incidence of newly emergent genotypic substitutions and phenotypic resistance to study drugs for virologic failures through Week 48 and 96.	Through week 48 and 96

Collaborators and Investigators

• Sponsor: Bristol-Myers Squibb
• Investigators: Study Director: Bristol-Myers Squibb, Bristol-Myers Squibb

Publications and helpful links

Helpful Links

• BMS Clinical Trial Patient Recruiting

Study record dates

Study Major Dates

• Study Start (Actual): July 31, 2012
• Primary Completion (Actual): January 22, 2013
• Study Completion (Actual): January 22, 2013

Study Registration Dates

• First Submitted: June 13, 2012
• First Submitted That Met QC Criteria: June 14, 2012
• First Posted (Estimated): June 15, 2012

Study Record Updates

• Last Update Posted (Actual): January 10, 2024
• Last Update Submitted That Met QC Criteria: January 8, 2024
• Last Verified: January 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Molecular Mechanisms of Pharmacological Action; Anti-Infective Agents; Antiviral Agents; Reverse Transcriptase Inhibitors; Nucleic Acid Synthesis Inhibitors; Enzyme Inhibitors; Anti-HIV Agents; Anti-Retroviral Agents; Protease Inhibitors; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 Enzyme Inhibitors; HIV Protease Inhibitors; Viral Protease Inhibitors; Tenofovir; Emtricitabine; Ritonavir; Lamivudine; Atazanavir Sulfate
• Other Study ID Numbers: AI424-494; 2011-006187-47 (EudraCT Number)